Experimental Drug for Ewing’s Sarcoma to Inhibit Prostate Cancer Metastasis
Researchers from the Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center (GUMC) have found that an experimental drug for treating Ewing’s Sarcoma is effective in preventing the metastasis of prostate cancer. The results of the study are published in April 29th 2011 issue of the PLoS ONE.
The lead researcher of the study informed that the drug has the ability to inhibit the cancer cells from spreading to fresh locations in the body. The drug is YK-4 279.
Breakage of the genes ETV1 and ERG to form a fusion gene results in the production of a protein which makes the prostate cancer cells more aggressive. It is seen in 40-70 percent cases. As Ewing’s Sarcoma metastasis also involves the role of fusion gene, the researchers used YK-4 279 for this cancer as well.
It was also learnt that presence of absence of the hormone androgen did not affect the beneficial influence of this drug.